PrasFarma

What PrasFarma does

PrasFarma (PRASFARMA, S.L.) is a Spanish pharmaceutical Contract Manufacturing Organization (CMO) headquartered in Cerdanyola del Vallès, Barcelona, with a 7,000 square metre manufacturing plant in Manlleu, Barcelona, and a 400+ square metre pilot development plant. The company has been operating for more than 80 years (founded around 1941-1943) and provides development, co-development, manufacturing, and clinical trial batch supply services for cytotoxic and high potency pharmaceutical products, with particular depth in oncology and pain therapy specialities.

The production portfolio spans three categories: cytostatic oral forms (hard capsules, sachets, film-coated tablets, sugar-coated tablets) with 510 million units per year capacity; cytostatic parenteral forms (liquids and lyophilized products) at 11 million units per year; and non-cytostatic parenteral forms (vials, ampoules, prefilled syringes) at 10 million units per year. The company holds AEMPS, ANVISA, Generalitat de Catalunya, and ISO 14001:2015 certifications, and operates within a B2B professional services and licensing model. Revenue mechanics comprise fee-for-service CMO contracts (development through commercialization, with flexible scope), production of guaranteed clinical trial batches for both startups and multinational pharmaceutical clients, and licensing of an own-product portfolio to third parties for royalty income.

Products reach more than 65 countries through an international distribution partner network with intensive coverage of Central and Eastern Europe, North Africa, the Middle East, Asia, and Latin America. The company serves a hybrid customer base spanning pharmaceutical companies requiring cytotoxic manufacturing, drug development companies needing galenic expertise and clinical trial supply, and regional distribution partners. Headcount is reported in the 11-50 range and the entity is privately held with no disclosed funding rounds, acquisitions, or parent company.

Name

PrasFarma

Legal name

PRASFARMA, S.L.

Website

https://prasfarma.com

Company type

Private

Founded year

1943

Operating status

Operating

Headcount range

11–50 employees

Short description

PrasFarma is a Spanish pharmaceutical Contract Manufacturing Organization (CMO) specializing in cytotoxic and high potency products, particularly oncology and pain therapy. It serves pharmaceutical companies worldwide via development, co-development, manufacturing, and clinical trial batch services, reaching 65+ countries through distribution partners.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Scientific Research and Development Services (5417)

akta.pro industry

PRIMARYHLAGAAAA

Clinical CROs (Phase I–IV)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAJAOAM

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

Keywords

• Pharmaceutical contract manufacturing
• Cytotoxic drug manufacturing
• Oncology injectable production
• Clinical trial batch supply
• Pharmaceutical licensing services

Headquarters

HQ city

Manlleu

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Organization (CMO) Services: Full-service pharmaceutical manufacturing including development, co-development, clinical trials, production, logistics, and regulatory affairs support. Flexible agreements covering all or specific phases of the value chain.
2. Product Licensing: Prasfarma has developed a portfolio of own products available for licensing to third parties.
3. Clinical Trial Batch Production: Production of guaranteed optimal batches for clinical trials for both small start-ups and large multinational pharmaceutical companies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

PrasFarma is a pharmaceutical Contract Manufacturing Organization that develops, co-develops, manufactures, and supplies cytostatic and non-cytostatic products (oral and parenteral forms), with specialized capabilities in cytotoxic and high-potency pharmaceuticals for oncology and pain therapy. It also offers clinical-trial batch production, regulatory affairs support, logistics, and licensing of its own product portfolio to third parties.

Product overview

PrasFarma is a pharmaceutical Contract Manufacturing Organization (CMO) specializing in cytotoxic and high potency products, particularly in Oncology and High Potency Products. The company offers a comprehensive range of pharmaceutical services including Development, Co-development, Regulatory Affairs, Clinical Research, Production, Logistics, Marketing, and Licensing. The product portfolio consists of three main product categories: Cytostatic Oral Forms (Hard Capsules, Sachets, Film Coated Tablets, Sugar Coated Tablets with 510 million units/year capacity), Cytostatic Parenteral Forms (Liquids and Lyophilized with 11 million units/year capacity), and Non-Cytostatic Parenteral Forms (Vials, Ampoules, Prefilled Syringes with 10 million units/year capacity). The company operates from headquarters in Cerdanyola del Vallès and a 7,000 square metre manufacturing plant in Manlleu, Barcelona, with a 400+ square metre pilot development plant.

Differentiator

Problem solved

Functional benefit

Products and services

• Cytostatic Oral Forms Oral pharmaceutical forms of cytostatic drugs including hard capsules, sachets, film coated tablets, and sugar coated tablets, manufactured at a capacity of 510 million units per year. Targeted at pharmaceutical companies requiring cytotoxic oral dosage form supply.
• Cytostatic Parenteral Forms Injectable cytostatic pharmaceutical forms including liquids and lyophilized products, manufactured at a capacity of 11 million units per year. Targeted at pharmaceutical companies requiring cytotoxic parenteral products.
• Non-Cytostatic Parenteral Forms Non-cytotoxic injectable pharmaceutical forms including vials, ampoules, and prefilled syringes, manufactured at a capacity of 10 million units per year. Targeted at pharmaceutical companies requiring non-cytotoxic sterile injectable products.
• Contract Manufacturing Organization (CMO) Services Comprehensive contract manufacturing organization services for pharmaceutical companies, providing development, co-development, regulatory affairs, clinical trial batch supply, production, logistics, and marketing support. Serves both small start-ups and large multinational pharmaceutical companies.
• Pharmaceutical Development Services Galenic formulation and pharmaceutical development services, including collaboration with academic and research centres, creation of new pharmaceuticals, and new forms of administration development. Targets pharmaceutical companies seeking R&D and formulation expertise.
• Co-Development Services Partnership-based co-development of new drugs or existing drugs with new forms of administration. Targets pharmaceutical companies seeking shared R&D and formulation partnerships.
• Clinical Trials Batch Supply Services Guaranteed optimal production of batches for clinical trials, serving both small start-ups and large multinational pharmaceutical companies. Includes clinical research support for clinical-stage drug development.
• Regulatory Affairs Services Regulatory affairs support for pharmaceutical product development, registration, and approval, leveraging PrasFarma's AEMPS and ANVISA certifications. Targets pharmaceutical companies seeking regulatory strategy and submission support.
• Pharmaceutical Product Licensing Licensing of PrasFarma's portfolio of own-developed pharmaceutical products to third parties for commercialization in specific markets or regions. Targets pharmaceutical companies and distributors seeking in-licensing opportunities.

Quantifiable outcome

• Production capacity of 510 million tablets, capsules, and sachets per year for oral forms
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• International Distribution PartnerscoreChannel Partner/ Reseller/ DistributorPrasfarma's portfolio is available through distribution partners who distribute products in more than 65 countries around the world. Partners have intensive operations in Central and Eastern Europe, North Africa, as well as the Middle East, Asia, and Latin America.
• StartupsminorStrategic or Co-development PartnerPrasfarma collaborates with startups to develop their innovative projects in the pharmaceutical sector.
• UniversitiesminorStrategic or Co-development PartnerPrasfarma collaborates with universities for pharmaceutical development projects and research initiatives.
• Pharmaceutical CompaniescoreStrategic or Co-development PartnerPrasfarma collaborates with pharmaceutical companies to develop innovative projects, including both small start-ups and large multinationals requiring drug development and clinical trial batch production services.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Catalent: Global CDMO providing development, manufacturing, and clinical supply services across a wide range of dosage forms including injectables and oral solids. Comparable to PrasFarma as a contract manufacturer serving pharma clients, though at materially larger scale.
• Lonza: One of the world's largest CDMOs offering mammalian and microbial biologics as well as small molecule and parenteral manufacturing. Comparable to PrasFarma in providing contract manufacturing and development services, but at substantially greater scale and breadth.
• Siegfried Holding: Swiss-listed CDMO providing API and finished drug product manufacturing including sterile filling. Comparable to PrasFarma in offering full-service contract manufacturing for pharmaceutical companies, though with broader scale and a public capital base.
• Piramal Pharma Solutions: Contract development and manufacturing arm of Piramal Pharma, offering sterile injectables, oral solids, and high-potency manufacturing. Comparable to PrasFarma in cytotoxic and high-potency manufacturing services, though at greater geographic and therapeutic scale.

Direct peers

• Recipharm: European-headquartered CDMO offering contract development and manufacturing services across oral solids, sterile injectables, and other dosage forms. Directly comparable to PrasFarma as a mid-sized European CMO serving pharma clients with multi-jurisdictional operations.
• Corden Pharma: Full-service CDMO offering APIs, excipients, drug products, and packaging across oral, sterile, peptide, and highly potent categories. Closely comparable to PrasFarma given the high-potency/cytotoxic manufacturing overlap and contract pharma services model.
• Almac Group: Privately held CDMO offering pharmaceutical development, manufacturing, and clinical services. Comparable to PrasFarma in serving both small biotechs and large multinationals with development and commercial supply.
• Aenova Group: European CDMO focused on solid and semi-solid dosage forms as well as sterile and biologics manufacturing. Comparable to PrasFarma as a mid-sized European contract manufacturer serving pharma clients across multiple dosage forms.

Regional players

• Laboratorio Reig Jofre: Spanish pharmaceutical company with contract manufacturing capabilities and proprietary specialty pharma products. Comparable to PrasFarma as a Spain-based pharmaceutical manufacturer operating in similar therapeutic and contract service categories.
• Insud Pharma: Spanish-headquartered pharmaceutical group with CDMO operations and proprietary finished dose products. Comparable to PrasFarma as a Spain-based player offering contract manufacturing services and finished pharmaceutical products in overlapping therapeutic categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PrasFarma